Akorn, Inc. announced that the US Food and Drug Administration has granted approval for Akorn's Abbreviated New Drug Application (ANDA) for Adenosine injection USP, 3 mg/mL.
Adenosine injection is indicated for supraventricular tachycardia in cardiac patients. Annual sales for Adenosine injection were approximately $22 million in 2007, according to IMS sales data.
Arthur S. Przybyl, Akorn's president and chief executive officer stated, "We are pleased to announce the ANDA approval for Adenosine. This product is manufactured at our Decatur, Illinois manufacturing facility and represents another important addition to our injectable product line. We expect to launch Adenosine in 2009."
Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.